Source: PR Newswire

Latigo received $150M in Series B Funding

Read full article »

Latigo's Competitors | Latigo's News | Latigo's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Nima Farzan

CEO Approval Rating

90/100

Latigo is a California-based clinical-stage biotechnology company that researches and develops non-opioid medicines for the treatment of chronic pain.